EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSPPRG00000001640
Gene Symbol: MAP3K1
4 Cross references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSPPRG00000023297
Gene Symbol: MAP3K10
4 Cross references
185 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSPPRG00000001122
Gene Symbol: MAP3K12
4 Cross references
254 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSPPRG00000007780
Gene Symbol: MAP3K13
4 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSPPRG00000001889
Gene Symbol: MAP3K5
4 Cross references
203 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSPPRG00000015038
Gene Symbol: MAP3K8
4 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSPPRG00000006080
Gene Symbol: MAP3K9
4 Cross references
194 Possible Orthologues:

Monoamine Oxidase A

Ensembl ID : ENSPPRG00000017638
Gene Symbol: MAOA
3 Cross references
146 Possible Orthologues:

Monoamine Oxidase B

Ensembl ID : ENSPPRG00000013398
Gene Symbol: MAOB
4 Cross references
330 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSPPRG00000002430
Gene Symbol: MGLL
3 Cross references
208 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSPPRG00000002089
Gene Symbol: MLNR
3 Cross references
165 Possible Orthologues:

Myeloperoxidase

Ensembl ID : ENSPPRG00000007956
Gene Symbol: MPO
3 Cross references
181 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).